These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
645 related articles for article (PubMed ID: 33990512)
21. Small Interfering RNA Therapeutic Inclisiran: A New Approach to Targeting PCSK9. German CA; Shapiro MD BioDrugs; 2020 Feb; 34(1):1-9. PubMed ID: 31782112 [TBL] [Abstract][Full Text] [Related]
22. The clinical effects of inclisiran, a first-in-class LDL-C lowering siRNA therapy, on the LDL-C levels in Chinese patients with hypercholesterolemia. Luo Z; Huang Z; Sun F; Guo F; Wang Y; Kao S; Yang G; Huang J; Li J; Zhao S; He Y J Clin Lipidol; 2023; 17(3):392-400. PubMed ID: 37164838 [TBL] [Abstract][Full Text] [Related]
23. Inclisiran for the Treatment of Heterozygous Familial Hypercholesterolemia. Raal FJ; Kallend D; Ray KK; Turner T; Koenig W; Wright RS; Wijngaard PLJ; Curcio D; Jaros MJ; Leiter LA; Kastelein JJP; N Engl J Med; 2020 Apr; 382(16):1520-1530. PubMed ID: 32197277 [TBL] [Abstract][Full Text] [Related]
25. An update on inclisiran for the treatment of elevated LDL cholesterol. Barkas F; Ray K Expert Opin Pharmacother; 2024 Mar; 25(4):349-358. PubMed ID: 38549399 [TBL] [Abstract][Full Text] [Related]
26. Long-term efficacy and safety of inclisiran in patients with high cardiovascular risk and elevated LDL cholesterol (ORION-3): results from the 4-year open-label extension of the ORION-1 trial. Ray KK; Troquay RPT; Visseren FLJ; Leiter LA; Scott Wright R; Vikarunnessa S; Talloczy Z; Zang X; Maheux P; Lesogor A; Landmesser U Lancet Diabetes Endocrinol; 2023 Feb; 11(2):109-119. PubMed ID: 36620965 [TBL] [Abstract][Full Text] [Related]
27. Small interfering RNA to proprotein convertase subtilisin/kexin type 9: transforming LDL-cholesterol-lowering strategies. Brandts J; Ray KK Curr Opin Lipidol; 2020 Aug; 31(4):182-186. PubMed ID: 32487819 [TBL] [Abstract][Full Text] [Related]
28. New LDL-cholesterol lowering therapies: pharmacology, clinical trials, and relevance to acute coronary syndromes. Sahebkar A; Watts GF Clin Ther; 2013 Aug; 35(8):1082-98. PubMed ID: 23932550 [TBL] [Abstract][Full Text] [Related]
29. Inclisiran in lipid management: A Literature overview and future perspectives. Scicchitano P; Milo M; Mallamaci R; De Palo M; Caldarola P; Massari F; Gabrielli D; Colivicchi F; Ciccone MM Biomed Pharmacother; 2021 Nov; 143():112227. PubMed ID: 34563953 [TBL] [Abstract][Full Text] [Related]
36. Proprotein convertase subtilisin/kexin type 9-inhibition across different patient populations. Stürzebecher PE; Laufs U Curr Opin Lipidol; 2024 Aug; 35(4):179-186. PubMed ID: 38547336 [TBL] [Abstract][Full Text] [Related]
37. Alirocumab Treatment and Achievement of Non-High-Density Lipoprotein Cholesterol and Apolipoprotein B Goals in Patients With Hypercholesterolemia: Pooled Results From 10 Phase 3 ODYSSEY Trials. Bays HE; Leiter LA; Colhoun HM; Thompson D; Bessac L; Pordy R; Toth PP J Am Heart Assoc; 2017 Aug; 6(8):. PubMed ID: 28862926 [TBL] [Abstract][Full Text] [Related]
38. Targeting PCSK9 as a promising new mechanism for lowering low-density lipoprotein cholesterol. Della Badia LA; Elshourbagy NA; Mousa SA Pharmacol Ther; 2016 Aug; 164():183-94. PubMed ID: 27133571 [TBL] [Abstract][Full Text] [Related]
39. Management of hypercholesterolemia for prevention of atherosclerotic cardiovascular disease: focus on the potential role of recombinant anti-PCSK9 monoclonal antibodies. Verma DR; Brinton EA Rev Cardiovasc Med; 2014; 15(2):86-101; quiz 101. PubMed ID: 25051126 [TBL] [Abstract][Full Text] [Related]
40. Efficacy and safety of add on therapies in patients with hypercholesterolemia undergoing statin therapy. Tomlinson B; Chan P; Zhang Y; Lam CWK Expert Opin Pharmacother; 2020 Dec; 21(17):2137-2151. PubMed ID: 32772741 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]